Ibrance (palbociclib) Step Therapy
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and step therapy coverage for Ibrance in members, primarily those with HR-positive, HER2-negative advanced, metastatic, recurrent unresectable, or stage IV breast cancer. Members new to Ibrance must satisfy applicable coverage criteria, while members currently receiving Ibrance may continue therapy when continuation conditions are met.
The July 2026 revision removed the criterion requiring Ibrance to be used in combination with an aromatase inhibitor or Faslodex.
The policy includes new step therapy criteria requiring consideration of Kisqali and Verzenio for applicable new-to-therapy members.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.